Table 1. Antimicrobial susceptibility rates in P. aeruginosa bacteremia.
| Characteristics | Total (n = 295) | 2009–2012 (n = 87) | 2013–2016 (n = 94) | 2017–2020 (n = 114) | P |
|---|---|---|---|---|---|
| Amikacin | 269 (91.2) | 77 (88.5) | 89 (94.7) | 103 (90.4) | 0.316 |
| Gentamicin | 246 (83.4) | 75 (86.2) | 82 (87.2) | 89 (78.1) | 0.147 |
| Imipenem | 220 (74.6) | 71 (81.6) | 65 (69.1) | 84 (73.7) | 0.151 |
| Meropenem | 222 (75.3) | 72 (82.8) | 66 (70.2) | 84 (73.7) | 0.131 |
| Cefepime | 228 (77.3) | 68 (78.2) | 76 (80.9) | 85 (74.6) | 0.551 |
| Ceftazidime | 226 (76.6) | 67 (77.0) | 73 (77.7) | 86 (75.4) | 0.926 |
| Piperacillin-tazobactam | 193 (65.4) | 57 (65.5) | 64 (68.1) | 72 (63.2) | 0.758 |
| Ticarcillin-clavulanate | 99 (33.6) | 23 (26.4) | 37 (39.4) | 39 (34.2) | 0.181 |
| Ciprofloxacin | 211 (71.5) | 70 (80.5) | 63 (67.0) | 78 (68.4) | 0.087 |
| Aztreonam | 167 (56.6) | 57 (65.5) | 52 (55.3) | 58 (50.8) | 0.111 |
| Colistin | 294 (99.7) | 87 (100) | 94 (100) | 113 (99.1) | 1.000 |
Values are presented as number of patients (%).